The U.S. Food and Drug Administration has approved the first drug to treat fatty liver disease (NAFLD). This was reported by health day.
Inflammation caused by obesity, diabetes, and high blood pressure can cause nonalcoholic fatty liver disease, also known as fatty liver: a disease in which fat builds up in the liver and causes scarring. Over time, this leads to dysfunction of the organ.
Resdiffra reduces fat accumulation in the liver by activating thyroid hormone receptors in the liver. It was effective in 24-36% of participants in a clinical trial. The drug will be a supplement to diet and physical activity. Approximately eight million Americans have nonalcoholic steatohepatitis. These patients now have their first treatment.
Side effects include diarrhea, nausea, liver and gallbladder problems. It may also interfere with the work of statins, which are drugs that lower blood cholesterol, so the decision to prescribe Resdiffra should be made by a doctor.
previously male Established Living 40 years after a heart transplant is a record.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.